These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 7879631

  • 1. New perspectives on biological treatment of schizophrenia.
    Lingjaerde O.
    Acta Psychiatr Scand Suppl; 1994; 384():102-7. PubMed ID: 7879631
    [Abstract] [Full Text] [Related]

  • 2. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A.
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [Abstract] [Full Text] [Related]

  • 9. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT.
    Turk Psikiyatri Derg; 2009 Oct; 20(2):175-82. PubMed ID: 19504368
    [Abstract] [Full Text] [Related]

  • 10. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 11. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.
    Encephale; 2001 Feb; 27(1):53-9. PubMed ID: 11294039
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR, Chen L.
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.
    Clin Ther; 2005 Oct; 27 Suppl A():S16-24. PubMed ID: 16198197
    [Abstract] [Full Text] [Related]

  • 18. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
    Millan MJ.
    J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
    [Abstract] [Full Text] [Related]

  • 19. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC.
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [Abstract] [Full Text] [Related]

  • 20. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS, Awasthi AK.
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.